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Abstract 
Background Most clinical risk stratification models are based on measurement at a 
single time-point rather than serial measurements. Artificial intelligence (AI) is able 
to predict one-dimensional outcomes from multi-dimensional datasets. Using data 
from GARFIELD-AF registry, a new AI model was developed for predicting clinical 
outcomes in atrial fibrillation (AF) patients up to 1 year based on sequential measures 
of PT-INR within 30 days of enrolment. 
Methods and results Patients with newly diagnosed AF who were treated with 
vitamin K antagonists (VKA) and had at least 3 measurements of PT-INR taken over 
the first 30 days after prescription were analyzed. The AI model was constructed with 
multilayer neural network including long short-term memory (LSTM) and one-
dimensional convolution layers. The neural network was trained using PT-INR 
measurements within days 0–30 after starting treatment and clinical outcomes over 
days 31–365 in a derivation cohort (cohorts 1–3; n = 3185). Accuracy of the AI model 
at predicting major bleed, stroke/SE, and death was assessed in a validation cohort 
(cohorts 4–5; n = 1523). The model's c-statistic for predicting major bleed, stroke/SE, 
and all-cause death was 0.75, 0.70, and 0.61, respectively. 
Conclusions Using serial PT-INR values collected within 1 month after starting VKA, 
the new AI model performed better than time in therapeutic range (TTR) at predicting 
clinical outcomes occurring up to 12 months thereafter. Serial PT-INR values contain 
important information that can be analyzed by computer to help predict adverse 
clinical outcomes. 
Keywords atrial fibrillation (AF), artificial intelligence (AI), machine learning 
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Introduction 
In chronic diseases such as atrial fibrillation (AF) risk stratification using prediction 
models is useful for clinical decision making. Several models predict clinical events 
such as stroke and bleeding.
1–3
 The CHA2DS2-VASc and HAS-BLED scores are 
widely used to select suitable AF patients for oral anticoagulation (OAC).
4–6
 However, 
some of the variables in these scoring systems are not consistently related to 
outcomes.
7
 Novel machine learning technology has facilitated the development of 
more accurate models such as the GARFIELD-AF risk model.
8
 However, these 
models incorporate data obtained at a single time-point, baseline. Although computers 
can process multi-dimensional data such as changes of variables over time, few 
models have used these inputs to predict future clinical events.
9,10
 
 
Vitamin K antagonists (VKAs) continue to be prescribed for the prevention of stroke 
in patients with AF, despite the more recent introduction of non-VKA oral 
anticoagulants (NOACs).
11,12
 VKAs are the only recommended choice of OAC for AF 
patients with hemodynamically overt mitral stenosis and mechanical heart valve. 
Clinicians adjust the dose of VKA based on an individual patient's prothrombin time 
international normalized ratio (PT-INR) at each visit. Time in therapeutic range 
(TTR) is widely used to standardize the effects of VKA therapy over periods beyond 
6 months.
13–17
 Various bleeding risk scores feature a TTR component to enhance 
accuracy,
18
 and TTR has predictive power for thrombotic and bleeding events.
19,20
 
However, information on serial changes in PT-INR during early-phase VKA therapy, 
which may reflect many occult clinical characteristics of patients such as 
genotype,
21,22
 concomitant medications,
23
 and lifestyle,
24
 were not included in these 
TTR-based models. 
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Advances in artificial intelligence (AI) using recurrent neural networks (RNN) allow 
the identification and translation of multi-dimensional data including time-series data 
directly into meaningful models.
25
 Herein, we describe a new AI model for predicting 
clinical outcomes over 31–365 days after patient enrolment. The model evaluates 
serially measured PT-INR within the first 30 days of treatment only without other 
clinical parameters, using data from the largest multinational prospective registry in 
AF, Global Anticoagulant Registry in the Field (GARFIELD)-AF. The predictive 
accuracy of the AI model was compared with that of TTR. The working hypothesis 
was to test whether serially measured PT-INR in early phase can provide information 
to predict future clinical events. 
 
Methods 
Design 
The AI model was derived from prospective GARFIELD-AF data gathered in adults 
with newly diagnosed AF.
26
 Three independent AI models were developed with the 
same composite of neural network structure with multi-dimensional patient-level PT-
INR values obtained within the first 30 days after starting treatment. The model 
tabulated the clinical events of major bleed, ischemic stroke/systemic embolism (SE), 
and death occurring within days 31–365. 
 
Registry population 
GARFIELD-AF is an ongoing, international, prospective registry of newly diagnosed 
patients with AF at risk of stroke. The study design, baseline characteristics, and main 
results have been published.
26–29
 Eligible patients were adults aged >18 years who had 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz076/5671699 by St G
eorge's U
niversity of London user on 16 D
ecem
ber 2019
 6 
 
been diagnosed with nonvalvular AF within the previous 6 weeks and had at least one 
risk factor for stroke as judged by the investigator. Risk factors were not prespecified 
in the protocol. Any use of antithrombotic agents was shared decision between 
clinicians and patients only. Patients with a transient reversible cause of AF and those 
for whom follow-up was not envisaged were excluded. The present analysis was 
conducted in patients enrolled in GARFIELD-AF cohorts 1–5 between March 2010 
and August 2016. Data were extracted from the study database in November 2017. 
 
Study population 
Patients who received anticoagulation therapy with VKA and had 3 or more PT-INR 
measurements within the first 30 days after enrolment were included in the model. 
Patients were excluded if they had experienced any outcome events such as serious 
bleeding or stroke or died within the first 30 days. In this analysis day of first visit 
was set as day 0. Patients from cohorts 1–3 (recruited between March 2010 and 
October 2014) were included in the derivation cohort whereas those in cohort 4–5 
(recruited March 2014–August 2016) comprised the validation cohort. This study 
design was considered stringent because each GARFIELD-AF cohort exhibited 
substantial differences in terms of participating countries, use of anticoagulants, and 
outcomes.
30
 
 
Follow-up 
Collection of follow-up data occurred at 4-monthly intervals based on medical records 
and, sometimes, telephone interviews up to 24 months. The incidence of ischemic 
stroke, transient ischemic attack (TIA), SE, acute coronary syndrome (ACS), 
hospitalization, death (cardiovascular and non-cardiovascular), chronic heart failure 
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(CHF; occurrence or worsening), and bleeding (severity and location) was 
documented. An audit and quality control programme was applied, and data were 
examined for completeness and accuracy by the coordinating centre (TRI, London, 
UK). By design, 20% of all electronic case report forms in the GARFIELD-AF 
registry were monitored against source documentation at sites over the 8 years of 
recruitment and follow-up. 
 
Outcomes 
Outcome measures used in this analysis were major bleeding, stroke/SE, and all-cause 
death occurring between days 31 and 365. Major bleed was classified by investigators 
according to International Society on Thrombosis and Haemostasis definition.
31
 
Stroke/SE was defined as a combined end point of ischemic stroke, SE, and TIA. 
 
Artificial intelligence model 
The structure of neural networks for the AI model is shown in Figure 1A. To deal 
with serial data on raw PT-INR measurements, the AI model was constructed by 
stacking multiple layers of special neurons that can deal with time-dependent data, 
namely one-dimensional convolution layer and long short-term memory (LSTM) 
layer. The LSTM layer transfer rectified data to each neighboring neuron.
32
 This 
structure allows the layer to learn time-dependent data in sequential order. 
 
The neural network model was trained independently for each outcome event. For 
training, PT-INR measurement patterns for each individual patient were converted to 
a 30-dimension PT-INR vector as shown in Figure 1B. All PT-INR measurements 
obtained within the first 30 days were input to the model. The measured PT-INR 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz076/5671699 by St G
eorge's U
niversity of London user on 16 D
ecem
ber 2019
 8 
 
value was inserted into nth element of the 30-dimension vector, where n is the number 
of days after starting VKA. Unmeasured data-points were filled with 0. Each vector 
for patients was labelled with the occurrence of outcome (0 for no event and 1 for 
event for all three outcome measures) within days 31–365. The neural networks were 
trained with the multi-dimensional dataset of the PT-INR vector and outcome label as 
shown in Figure 1C. 
 
Model training 
The process of model training is shown in Figure 2. Training was performed using 
only patient data from the derivation cohort. The derivation cohort was further split 
into training (70%) and testing (30%) datasets. Training was performed for 500 
epochs and each training epoch included a mini-batch of 455 patients randomly 
selected from the training dataset. Conceptually, performance of the model is 
designed to improve by training with longer epochs. However, this approach can also 
result in overfitting. To avoid this pitfall and select the model with best performance, 
the model was evaluated using the testing dataset at the end of each epoch. The final 
model was that which performed best with the testing dataset. Performance was 
measured by calculating the c-statistics of the prediction model for all the data in 
testing dataset. No data from validation cohort were used for training. 
 
Model validation 
The derived models were validated by inputting the 30-day PT-INR vector and 
obtaining prediction scores for each outcome. Predicted outcomes were compared 
with the actual clinical course for each individual patient in the validation cohort. 
Receiver operating characteristic (ROC) curves were drawn to evaluate the predictive 
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value of the model. The threshold to achieve overall best accuracy for the model was 
determined and the model's sensitivity and specificity calculated at that threshold. To 
test the ability of the model to discriminate between high- and low-risk patients for 
each event, three sets of Kaplan-Meier plots were drawn for event rates stratified as 
high and low risk with the threshold. 
 
Ethics 
All trial protocols were approved by independent ethics committee and hospital-based 
institutional review board. The registry was conducted in accordance with the 
Declaration of Helsinki, local regulatory requirements, and International Conference 
on Harmonisation-Good Pharmacoepidemiological and Clinical Practice guidelines. 
All patients provided written informed consent to participate. 
 
Statistical analysis 
The neural network was constructed and trained using Keras framework version 2.1.6 
(https://keras.io) and TensorFlow version 1.8.0 as backend.
33
 The neural network was 
trained using the back-propagation supervised training algorithm. The loss function 
that was previously reported to reflect the c-statistics
34
 was minimized using the 
RMSprop optimizer. 
 
The c-statistics, the threshold to achieve best accuracy and corresponding accuracy, 
sensitivity, and specificity of the model at the threshold with its 95% confidence 
intervals (95% CI) were calculated by bootstrap procedure with 2000 bootstrap rounds 
using the pROC package of R version 3.5.1.
35
 Comparison of ROC curve between the 
AI model and TTR was performed similarly with pROC package. Kaplan-Meier plots 
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were produced using the survival package of R. All p-values were calculated by log-
rank test; a p-value <0.05 was considered statistically significant. 
 
Results 
Patients 
The flowchart of patient selection is shown in Figure 3. Of 14,437 de novo AF 
patients treated with VKA, 4806 had at least 3 PT-INR measurements within the first 
30 days and were included in the analysis. Ninety-eight patients were excluded (92 
with an outcome event within the first 30 days and 6 with missing information). Of 
the remainder, 3185 were eligible for inclusion in the derivation cohort and 1523 in 
validation cohort. Baseline characteristics are displayed in Table 1. There was no 
substantial intergroup difference in terms of patients' sex, age, body mass index (BMI), 
and left ventricular ejection fraction (LVEF). Patients with at least 3 PT-INR 
measurements during initial 30 days were slightly less likely to have paroxysmal AF 
and CHF than those with fewer than 3 INR measurements. No difference in baseline 
characteristics was noted between derivation and validation cohorts. 
 
Predictive value of artificial intelligence model 
ROC curve compiled for the validation cohort (Figure 4A) revealed that the AI model 
had a statistically higher predictive value compared with TTR with c-statistics for 
major bleeding and all-cause death 0.75 and 0.61, respectively (both p = 0.01 vs. 
TTR). A similar trend albeit nonsignificant was observed for stroke, with a c-statistic 
0.70 (p = 0.08 vs. TTR). Forest plots of 95% CI for AUC of ROC curves (Figure 4B) 
show that the AI model performed better than random; c-statistics for major bleed, 
stroke, and all-cause death were 0.75 (95% CI, 0.62–0.87), 0.70 (95% CI, 0.56–0.83), 
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and 0.61 (95% CI, 0.54–0.67), respectively, whereas TTR was not significantly 
different compared with random (for same outcomes: 0.47 [95% CI, 0.32–0.61], 0.47 
[95% CI, 0.31–0.64], and 0.48 [95% CI, 0.42–0.54], respectively). Table 2 shows the 
accuracies, sensitivities, and specificities for the best thresholds derived from the 
ROC curve for major bleed, stroke, and all-cause death. The model showed good 
predictive accuracy for major bleeding with a sensitivity 0.79 and specificity 0.78. 
These results were similar for the training dataset (Online Table 1, Online Figure 1A 
and 1B). 
 
Survival analysis 
Kaplan-Meier plots stratified by risk determined from the AI model are shown in 
Figure 5. The threshold of prediction score was calculated for each event to achieve 
the best accuracy according to the ROC curve. The best thresholds for major bleed, 
stroke/SE, and all-cause death were 0.27, 0.44, and 0.49, respectively. Note that these 
output values from our model are arbitrary numbers related to risk of future events but 
not actual probabilities. Patients who had a model output higher than or equal to 
threshold were classified as high risk and the remainder were low risk. Among 1523 
patients in the validation cohort, 354 were classified high risk for major bleeding, 738 
for stroke, and 560 for death. High-risk patients had higher cumulative event rates 
(major bleed, stroke/SE, and all-cause death) compared with low-risk patients. 
 
The same analysis was performed for the derivation dataset. No threshold calculations 
were performed for the derivation dataset and the same thresholds obtained from the 
validation dataset were used for this analysis. The results were similar, supporting the 
robustness of the threshold (Online Figure 2). 
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Discussion 
We created a new method to convert early time-series measurements of PT-INR to a 
long-term prediction model. The novel AI model, constructed with neural networks 
including 1-dimensional convolution and LSTM, garnered useful information from 
the raw PT-INR values and measurement dates over 30 days after VKA initiation and 
converted this to predict major bleeding events over the next 11 months. Although 
TTR is widely used to standardize VKA therapy over the long term,
14–17
 its accuracy 
for predicting future thrombotic/bleeding events is low.
36
 A previous report showed 
that GARFIELD-AF patients with 1-year TTR less than 65% had worse outcomes 
than those with greater values.
37
 Within 30 days, TTR has low predictive power 
because early-phase PT-INR values vary greatly due to a number of influencing 
factors including genetics,
21,22
 choice of commercial thromboplastin and coagulometer 
device,
38–40
 and patients' lifestyles.
41
 With the use of AI, we show here the presence of 
important information in raw PT-INR patterns over first 30 days that can predict 
clinical events occurring from days 31 to 365.  
 
Multiple useful models exist to predict clinical outcomes in patients with AF.
1–3,8,42,43
 
However, most use single time-point data. HAS-BLED score, on the other hand, does 
include time-series data on PT-INR in the guise of labile PT-INR, which is expressed 
by TTR.
3
 Our AI model using time-series PT-INR values has better predictive power 
than TTR for major clinical events, at least in the early phase of VKA initiation. Even 
with multi-dimensional data including 31 datasets our AI model output is a prediction 
score given as a single value. Thus, output of the new model may be included in 
conventional scoring models by introducing a cutoff, similarly to integration of 
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TTR.
18
 ROC analysis in validation cohort revealed that our AI model has modest 
predictive power with a best c-statistic 0.78, for major bleeding. However, the model 
could be usefully incorporated into previous models and thereby improve their 
accuracy, as has been done with TTR.
18
 Our prediction model could expand to 
automatic prediction of clinical outcomes from multi-dimensional data when 
incorporated into electrical patient recording systems, for example. Since our models 
are able to predict clinical outcomes in the early phase of treatment, they may 
discriminate patients who are unsuitable for VKA therapy and suggest switching them 
to NOACs, which are associated with lower bleeding risk compared with VKA. 
 
Our novel AI model comprising a neural network can efficiently connect multiple 
time-dependent measurements to clinical outcomes to form a prediction model. 
Although in this study the network was used only to learn PT-INR patterns as specific 
target, the same structure may have the ability to convert other multi-dimensional 
time-dependent measurements to prediction models. Therefore, the network may 
provide a new means to incorporate time-dependent data in prediction models. 
 
Output values from our AI model are related to risk of future events but not their 
probability. Therefore, calibration of the model with typical Hosmer-Lemeshow 
goodness-of-fit (GOF) test is not feasible.  
 
Study limitations 
Several limitations of this analysis should be noted. First, validation of the AI models 
was performed using datasets derived from the GARFIELD-AF registry. External 
validations of the AI model were not conducted. Thus, validity of this model beyond 
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GARFIELD-AF patients is unknown. On the other hand, large dissimilarities between 
cohorts 1–3 and 4 and 5 were noted, suggesting that our model is sufficiently robust to 
apply in daily clinical practice. PT-INR within 30 days may be influenced by 
concomitant dosing with parenteral anticoagulants. However, our model attempted to 
account for all influencing factors beyond the effects of VKA. We hope that other 
researchers will test our model's performance in external datasets. 
 
Second, the AI model was trained only with PT-INR data, and did not include other 
information such as sex, age, biomarkers, concomitant drugs, or other serially 
measured values. Although consecutive patient data were analyzed, unrecognized 
confounders may exist. Many other known risk factors for adverse outcome events 
were not considered in our models. 
Third, by selecting only patients with more than 3 PT-INR measurements within 30 
days, two thirds of the entire cohort were excluded, which could introduce selection 
bias. Furthermore, patients do not necessarily remain stable after day 31 and our 
model cannot capture changes at time-points later than day 31. Future studies will 
examine the impact of time periods beyond 30 days in relation to AI risk prediction.  
 
Fourth, although our results suggest the presence of crucial information within the PT-
INR measurement pattern to predict patients' clinical course, the nature of that 
information is unknown. It might be present in the target PT-INR value, PT-INR 
fluctuations, PT-INR measurement frequency, or elsewhere.  
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Fifth. The c-statistics, sensitivity, and specificity of our models are far from perfect. 
Further studies to improve predictive accuracy possibly by adding other clinical 
characteristics and measurements are necessary. 
 
Sixth, statistical significance was not achieved in either the derivation or validation 
cohort in comparison with TTR for prediction of all-cause death and stroke. This 
could be explained by low numbers of events limiting statistical power. Moreover, 
even though the number of deaths observed was not low, they could have been caused 
by factors not related to anticoagulation. Validation of the model in larger cohorts 
with higher numbers of events may demonstrate better predictive power for death and 
stroke. Despite these limitations, our results suggest that serially measured PT-INR 
values within 30 days contain information enabling us to predict serious bleeding 
outcomes up to 1 year. Trained AI may thus be able to detect individuals at high risk 
for major adverse cardiac events early in the treatment course. 
 
Conclusions 
In AF patients treated with VKA we developed new AI models to predict all-cause 
death, stroke, and major bleeding events occurring between months 2 and 12. The 
models' predictive accuracy was greatest for major bleeding, followed by all-cause 
mortality and stroke/SE. Our results imply that AI can capture important information 
to predict future outcomes from early-phase PT-INR measurements. 
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Table 1 Patients' baseline demographics and clinical characteristics* 
 ≥3 PT-INRs 
(N=4708) 
0–2 PT-INRs 
(N=9630) 
≥3 PT-INRs Subgroup 
   Derivation 
(N=3185) 
Validation 
(N=1523) 
Sex, n (%)     
     Female 2085 (44.3) 4330 (45.0) 1420 (44.6) 665 (43.7) 
     Male 2623 (55.7) 5300 (55.0) 1765 (55.4) 858 (56.3) 
Age at dx, years 72.1 (9.9) 70.0 (10.7) 72.2 (9.7) 72.0 (10.2) 
BMI, kg/m
2
 28.7 (5.9) 28.1 (5.7) 28.6 (5.7) 29.0 (6.1) 
LVEF, % 53.7 (12.9) 55.7 (12.7) 53.2 (13.2) 54.7 (12.2) 
Type of AF, n 
(%) 
    
     New 2409 (51.2) 4087 (42.4) 1706 (53.6) 703 (46.2) 
     Paroxysmal 798 (16.9) 2207 (22.9) 567 (17.8) 231 (15.2) 
     Permanent 877 (18.6) 1514 (15.7) 487 (15.3) 390 (25.6) 
     Persistent 624 (13.3) 1822 (18.9) 425 (13.3) 199 (13.1) 
CHF, n (%) 721 (15.3) 2149 (22.3) 466 (14.6) 255 (16.7) 
CAD, n (%) 878 (18.6) 1896 (19.7) 511 (16.0) 367 (24.1) 
ACS 461 (9.8) 872 (9.1) 292 (9.2) 169 (11.1) 
CHA2DS2-VASc 3.4 (1.5) 3.3 (1.5) 34 (1.5) 33 (1.4) 
HAS-BLED 1.4 (0.9) 1.4 (0.9) 15 (0.9) 14 (0.9) 
*Values are mean (SD) unless specified otherwise. 
ACS, acute coronary syndromes; BMI, body mass index; CAD, coronary artery disease; CHF, 
congestive heart failure; LVEF, left ventricular ejection fraction. 
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Table 2 Best predictive accuracies and corresponding sensitivities and 
specificities (95% CIs) for validation cohort 
AI Accuracy Sensitivity Specificity 
Major bleed 0.78 (0.40–0.92) 0.79 (0.50–1.00) 0.78 (0.39–0.93) 
Stroke 0.53 (0.24–0.98) 0.85 (0.31–1.00) 0.53 (0.23–0.99) 
All-cause death 0.64 (0.51–0.69) 0.63 (0.50–0.76) 0.65 (0.50–0.70) 
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Figure legends 
Figure 1 Structure of the neural network and input data for the model. Schematic 
illustration of the neural network model (A). Vector of 30 PT-INR measurements for 
4708 patients used as input to the model (B). The element at n
th
 dimension of the 
vector holds the PT-INR value measured on day n. Un-measured data-points were 
filled with 0. These pairs of PT-INR vectors labeled with outcome for each patient 
were used for model training (C). LSTM, long short-term memory; 1D convolution, 
one-dimensional convolution; INR, prothrombin time international normalized ratio. 
 
Figure 2 Model training process. Schematic illustration of the training process. 
Datasets are indicated with yellow, processes indicated with blue, and models derived 
in each epoch indicated with light red. The derivation cohort was further split into 
training dataset and testing dataset. Training was performed by mini-batch method 
using 455 as batch size. For each epoch, the derived model was compared with the 
best model derived with previous epochs using the testing datasets. Training was 
performed for 500 epochs and the best model using the testing dataset selected. 
 
Figure 3 Patient selection. Schematic illustration of patient selection process. VKA, 
vitamin K antagonist; PT-INR, prothrombin time international normalized ratio. 
 
Figure 4 ROC analysis of the AI model. Comparison of ROC curves compiled from 
AI model and TTR (A). Comparisons were performed using stratified bootstrap 
method with 2000 bootstrap rounds. Forest plots of AUC of the ROC curve for each 
outcome (B). The 95% CIs were calculated by stratified bootstrap method with 2000 
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bootstrap rounds. ROC, receiver operating characteristic; AUC, area under curve; CI, 
confidence interval. 
 
Figure 5 Cumulative event rates according to risk stratified by AI model. Kaplan-
Meier curves stratified with risk according to AI model for major bleed (A), stroke/SE 
(B), and all-cause death (C). The threshold for risk stratification was made by that 
which gave the best accuracy in the validation cohort for each outcome according to 
the ROC curve. The p-values were calculated by log-rank test. ROC, receiver 
operating characteristic; AUC, area under curve. 
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